HighTower Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$40.3M Buy
64,650
+5,725
+10% +$3.9M 0.04% 433
2026
Q1
$45.5M Buy
58,925
+12,838
+28% +$9.83M 0.05% 380
2025
Q4
$35.6M Buy
46,087
+356
+0.8% +$242K 0.04% 440
2025
Q3
$25.7M Buy
45,731
+1,944
+4% +$1.1M 0.03% 522
2025
Q2
$23M Buy
43,787
+12,514
+40% +$6.98M 0.03% 532
2025
Q1
$19.8M Buy
31,273
+971
+3% +$668K 0.03% 541
2024
Q4
$21.6M Sell
30,302
-2,723
-8% -$2.29M 0.03% 502
2024
Q3
$34.6M Sell
33,025
-2,351
-7% -$2.62M 0.05% 367
2024
Q2
$37.1M Buy
35,376
+1,204
+4% +$1.17M 0.06% 336
2024
Q1
$33.1M Sell
34,172
-409
-1% -$389K 0.05% 351
2023
Q4
$30.6M Sell
34,581
-606
-2% -$499K 0.05% 357
2023
Q3
$28.9M Buy
35,187
+818
+2% +$643K 0.05% 341
2023
Q2
$24.7M Buy
34,369
+8,751
+34% +$6.75M 0.05% 364
2023
Q1
$21M Sell
25,618
-5,140
-17% -$3.88M 0.05% 390
2022
Q4
$22.1M Buy
30,758
+3,125
+11% +$2.31M 0.05% 367
2022
Q3
$19M Buy
27,633
+1,361
+5% +$857K 0.05% 351
2022
Q2
$15.6M Sell
26,272
-2,907
-10% -$1.89M 0.04% 417
2022
Q1
$20.3M Sell
29,179
-611
-2% -$387K 0.05% 375
2021
Q4
$18.8M Buy
29,790
+7,908
+36% +$4.86M 0.04% 398
2021
Q3
$13.2M Buy
21,882
+1,363
+7% +$846K 0.04% 435
2021
Q2
$11.5M Buy
20,519
+14,383
+234% +$7.29M 0.03% 466
2021
Q1
$2.9M Sell
6,136
-4,747
-44% -$2.31M 0.01% 945
2020
Q4
$5.21M Buy
10,883
+538
+5% +$290K 0.02% 576
2020
Q3
$5.79M Sell
10,345
-1,137
-10% -$689K 0.03% 503
2020
Q2
$7.12M Sell
11,482
-449
-4% -$255K 0.04% 413
2020
Q1
$5.76M Sell
11,931
-1,227
-9% -$506K 0.04% 408
2019
Q4
$5M Buy
13,158
+3,083
+31% +$1.04M 0.03% 542
2019
Q3
$2.79M Buy
10,075
+59
+0.6% +$17.5K 0.02% 772
2019
Q2
$3.16M Sell
10,016
-8,840
-47% -$2.94M 0.02% 729
2019
Q1
$7.71M Buy
18,856
+5,575
+42% +$2.3M 0.05% 366
2018
Q4
$4.94M Sell
13,281
-15,699
-54% -$5.75M 0.04% 456
2018
Q3
$11.7M Buy
28,980
+10,223
+55% +$3.89M 0.08% 264
2018
Q2
$6.42M Buy
18,757
+6,363
+51% +$1.99M 0.05% 415
2018
Q1
$4.25M Buy
12,394
+2,426
+24% +$844K 0.04% 520
2017
Q4
$3.78M Sell
9,968
-1,092
-10% -$442K 0.03% 588
2017
Q3
$4.95M Buy
11,060
+2,457
+29% +$1.17M 0.04% 465
2017
Q2
$4.17M Buy
8,603
+1,085
+14% +$475K 0.04% 520
2017
Q1
$2.92M Buy
7,518
+2,625
+54% +$973K 0.03% 619
2016
Q4
$1.8M Buy
4,893
+698
+17% +$265K 0.02% 740
2016
Q3
$1.68M Buy
4,195
+863
+26% +$346K 0.02% 722
2016
Q2
$1.16M Sell
3,332
-5,719
-63% -$2.2M 0.01% 811
2016
Q1
$3.27M Sell
9,051
-7,387
-45% -$3.04M 0.01% 529
2015
Q4
$8.93M Buy
16,438
+4,815
+41% +$2.61M 0.11% 202
2015
Q3
$5.41M Buy
11,623
+1,087
+10% +$584K 0.07% 301
2015
Q2
$5.38M Buy
10,536
+3,787
+56% +$1.85M 0.09% 254
2015
Q1
$3.05M Buy
6,749
+542
+9% +$230K 0.05% 454
2014
Q4
$2.55M Buy
6,207
+167
+3% +$65.7K 0.04% 505
2014
Q3
$2.18M Buy
6,040
+1,144
+23% +$383K 0.04% 524
2014
Q2
$1.38M Buy
4,896
+187
+4% +$55.4K 0.02% 688
2014
Q1
$1.41M Buy
4,709
+1,076
+30% +$332K 0.03% 626
2013
Q4
$1M Buy
+3,633
New +$1.04M 0.02% 696

Other funds holding REGN

HighTower Advisors's REGN Position: Q2 2026 in Review

HighTower Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 9.7% in Q2 2026, buying an estimated $3.9M and bringing the position to 64,650 shares worth $40.3M. The position accounts for 0.04% of the portfolio, ranked #433.

HighTower Advisors first reported a position in REGN in Q4 2013 and has held it in 51 quarters since. The position peaked at $45.5M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • HighTower Advisors held 64,650 shares of Regeneron Pharmaceuticals worth $40.3M as of Q2 2026.
  • HighTower Advisors bought 5,725 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.9M.
  • Regeneron Pharmaceuticals made up 0.04% of HighTower Advisors's portfolio in Q2 2026, its #433 holding.
  • HighTower Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 51 quarters since.
  • HighTower Advisors's Regeneron Pharmaceuticals position peaked at $45.5M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.